Log in to your Inderes Free account to see all free content on this page.
Guard Therapeutics
1.60 SEK
+1.59 %
Less than 1K followers
GUARD
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Guard Therapeutics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -43.6 | -40.1 | -81.9 | -114.9 | -115.1 | -99.9 | - |
| EBIT | -44.3 | -40.3 | -81.9 | -114.9 | -115.1 | -99.9 | -107.2 |
| Profit before taxes | -45.2 | -40.3 | -82.0 | -112.8 | -113.3 | -96.1 | -108.9 |
| Net income | -45.2 | -40.3 | -82.0 | -112.8 | -113.3 | -96.1 | -108.9 |
| EPS | -13.73 | -12.53 | -17.63 | -15.34 | -10.80 | -8.27 | -6.04 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -100.5 % | -50.6 % | -46.7 % | -63.6 % | -169.8 % | -253.0 % | -267.9 % |
| ROI | -80.7 % | -44.2 % | -43.1 % | -55.7 % | -133.0 % | -172.4 % | -201.0 % |
Login required
This content is only available for logged in users